Merck Announces Trial and 2 Dow Movers Buzz Today

| + More Articles
  • Like on Facebook
  • Share on Google+
  • Share on LinkedIn

AT&T (NYSE:T), in November, saw Nokia Corporation’s (NYSE:NOK) Lumia 920, which uses Microsoft’s (NASDAQ:MSFT) operating system, as its third best selling product, said analyst T. Michael Walkley at Canaccord Genuity, according to Boy Genius, which also said that supplies of have been low in several areas.

Wal-Mart Stores (NYSE:WMT) began offering same-day delivery in October as it and others try to provide customers with instant gratification from online orders and to pull sales away from local competitors by racing to offer same-day deliveries, according to the Wall Street Journal. In addition, retailers are making contracts with third parties such as the United Parcel Service (NYSE:UPS) to obtain access to couriers and grocery delivery employees in cities such as Minneapolis, Philadelphia, and San Francisco.

Catalysts are critical to discovering winning stocks. Check out our newest CHEAT SHEET stock picks now.

Merck & Co. (NYSE:MRK) reports it has begun a Phase II/III clinical trial designed to study the safety and efficacy of MK-8931 versus placebo in patients with mild-to-moderate Alzheimer’s disease. MK-8931 is the firm’s novel investigational oral b-amyloid precursor protein site-cleaving enzyme inhibitor and is the first with this mechanism to advance to this stage of clinical research. EPOCH, the global, multi-center evaluation, is designed to initially evaluate the safety of MK-8931 in a cohort of 200 patients prior to advancing into a larger Phase III study.

Don’t Miss: Will This Purchase Boost Sales for GlaxoSmithKline?


More Articles About:

To contact the reporter on this story: staff.writers@wallstcheatsheet.com To contact the editor responsible for this story: editors@wallstcheatsheet.com

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business